Glioma isocitrate dehydrogenase type 1 (IDH) mutations resulted in specifically educated, dysfunctional dendritic cells via paracrine reprogramming of infiltrating monocytes, providing the basis for combinatorial immunotherapy concepts against IDH mutant gliomas.
[Neuro-Oncology]
